PMID- 23461699
OWN - NLM
STAT- MEDLINE
DCOM- 20140129
LR  - 20220331
IS  - 1365-2133 (Electronic)
IS  - 0007-0963 (Linking)
VI  - 169
IP  - 1
DP  - 2013 Jul
TI  - Evaluation of MYC status in oral lichen planus in patients with progression to 
      oral squamous cell carcinoma.
PG  - 106-14
LID - 10.1111/bjd.12303 [doi]
AB  - BACKGROUND: Malignant transformation of oral lichen planus (OLP) to oral squamous 
      cell carcinoma (OSCC) is controversial. C-MYC is a proto-oncogene involved in 
      various solid tumours, including OSCC. OBJECTIVES: To determine MYC status using 
      fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in OLP 
      lesions from 10 patients with progression to OSCC (group I) and to compare this 
      with OLP lesions from patients without progression to OSCC (group II). METHODS: 
      We constructed two tissue microarrays with 11 OSCC samples (group IA), 17 OLP 
      samples from the same patients (group IB) and 13 OLP specimens from 12 control 
      patients (group II). FISH evaluation of the MYC gains was determined in 100 
      nonoverlapping nuclei per sample. IHC evaluation was determined by calculating 
      the percentage C-MYC expression in the epithelial cells. RESULTS: OSCC samples 
      showed MYC copy number gains and C-MYC overexpression in 91% and 73% of cases, 
      respectively. MYC gains were detected in 47% of samples from group IB and were 
      absent from all samples from group II. C-MYC was overexpressed in 87% of cases 
      from group IB and in only 44% of control specimens (group II). The differences in 
      MYC status between groups IB and II were statistically significant. CONCLUSIONS: 
      OLP lesions in patients with progression to OSCC show MYC gains and C-MYC 
      overexpression. In patients with severe OLP, determining MYC status may predict a 
      subgroup of subjects with a higher risk of progression to OSCC.
CI  - (c) 2013 The Authors BJD (c) 2013 British Association of Dermatologists.
FAU - Segura, S
AU  - Segura S
AD  - Department of Dermatology, Hospital del Mar, Parc de Salut Mar, Passeig Maritim 
      25-29, 08003 Barcelona, Spain.
FAU - Rozas-Munoz, E
AU  - Rozas-Munoz E
FAU - Toll, A
AU  - Toll A
FAU - Martin-Ezquerra, G
AU  - Martin-Ezquerra G
FAU - Masferrer, E
AU  - Masferrer E
FAU - Espinet, B
AU  - Espinet B
FAU - Rodriguez, M
AU  - Rodriguez M
FAU - Baro, T
AU  - Baro T
FAU - Barranco, C
AU  - Barranco C
FAU - Pujol, R M
AU  - Pujol RM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*genetics/pathology
MH  - Case-Control Studies
MH  - Cell Transformation, Neoplastic/genetics/pathology
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lichen Planus, Oral/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Mouth Neoplasms/*genetics/pathology
MH  - Proto-Oncogene Mas
MH  - Proto-Oncogene Proteins c-myc/*metabolism
MH  - Retrospective Studies
EDAT- 2013/03/07 06:00
MHDA- 2014/01/30 06:00
CRDT- 2013/03/07 06:00
PHST- 2013/02/26 00:00 [accepted]
PHST- 2013/03/07 06:00 [entrez]
PHST- 2013/03/07 06:00 [pubmed]
PHST- 2014/01/30 06:00 [medline]
AID - 10.1111/bjd.12303 [doi]
PST - ppublish
SO  - Br J Dermatol. 2013 Jul;169(1):106-14. doi: 10.1111/bjd.12303.